Flexible media system for gene therapy process development and high-titer AAV production in HEK293 cells
20 L Platinum UltraPAKTM Bioprocess container
TheraPEAK® T-VIVO® Cell Culture Medium, chemically defined, non-animal origin (NAO), serum-free, with recombinant proteins, 1 L bag
TheraPEAK® T-VIVO® Cell Culture Medium, chemically defined, non-animal origin (NAO), serum-free, with recombinant proteins, 1 L bottle
Cryopreserved human hepatocytes, plateable and interaction qualified are characterized for 3 major mechanisms of drug-drug interactions: transporter activity, enzyme activity, and induction potential (guaranteed to exhibit a 4 fold or greater change in induction activity), providing you with one product to meet more of your hepatocyte DDI study needs. Each ampule contains >5 million cells.
Chemically defined, non-animal origin (NAO), serum-free medium
-
MDL - Customer Facing Presentation - AssetCustomer Facing Deck - Custom Media Solutions
-
MDL - Customer Facing Presentation - AssetCustomer Facing Deck - Custom Media Solutions
-
End-to-end custom media and buffer solutionsBrochure on 3PIP, MDL and buffers
-
3PIP MDL - Asset - InfographicAn infographic illustrating Lonza’s end‑to‑end custom media and buffer solutions for CHO cells.
-
CD34+ Cells for Cell and Gene Therapy Process DevelopmentIn this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using research-grade CD34+ cells for cell and gene therapy process development. Please register to read.
-
CellBio Services – Custom Solutions to Meet Your Unique Research NeedsBrochure showcasing Lonza's CellBio Services capabilities including cell isolations and expansions, research grade media production, transfection services, and cell characterization.
-
Streamlining Your QC Testing: Automated Endotoxin Testing and Process OptimizationLearn how automating the liquid handling aspect of the endotoxin test helps you save time and reduce manual pipetting errors and retests. -
Evaluation of an Online PAT Co-Laboratory for Rapid Process Development: A Takeda Use StudyEvaluation of an Online PAT Co-Laboratory for Rapid Process Development – A Takeda use study Attendees will learn how to accelerate process development using the MAST® Automated Sampling System: • Automated process developed using a cross functional team with upstream and downstream engineers and analytical scientists • Measured product quality attributes including titer, aggregation, charge variants and post-translational modifications • Resulted in 10-fold reduction in total analytical time • Reduced FTE required by 65% -
TheraPRO CHOK1 presentationPresentation on TheraPRO CHOK1 for prospects and customers
-
Seamless Software Integration Allows for Enhanced Automation of the Entire Endotoxin Testing WorkflowEnable new and more efficient processes by integrating an electronic batch record system along with endotoxin detection and analysis software.